Novartis

Redefining CML care at Novartis

Ad Copy

Some moments stay with you. For Insa Gathmann, it was seeing early data in the late 1990s that suggested something unprecedented was happening. At first, it felt almost too good to be true. Nearly three decades later, as she proudly retires from Novartis after an extraordinary 30+ year career, the lead biostatistician looks back on a targeted therapy that helped transform chronic myeloid leukemia treatment and redefine what was possible for many patients living with the disease. #30YearsofNovartis #Reimaginingmedicinetogether